ME Therapeutics Holdings Inc. is advancing its lead anti-G-CSF antibody candidate, h1B11-12, towards potential clinical trials. The company is currently developing a cell line for GMP production of h1B11-12, with completion expected in the second half of 2025. Simultaneously, ME Therapeutics is collaborating with advisors to identify a suitable patient population and trial design, which will inform the design of necessary nonclinical studies.
Expansion of Research Capabilities
In the coming weeks, ME Therapeutics will be moving into new lab and office space. This expansion will support ongoing research programs and enable the exploration of early-stage drug discovery opportunities to broaden the company's drug pipeline. The company intends to recruit additional scientific research staff to conduct R&D activities in the new facilities.
Strategic Partnerships and In-Licensing
ME Therapeutics is also exploring potential in-licensing and partnership opportunities to enhance its existing drug development pipeline. According to Dr. Salim Dhanji, CEO of ME Therapeutics, the company is "excited with the progress we are continuing to make with our existing drug development pipeline as well as our drug discovery and in-licensing and partnership opportunities," and is "committed to continuing the growth of the Company into a biotechnology company with a strong drug development pipeline that can provide significant value to our shareholders."
About ME Therapeutics
ME Therapeutics is focused on developing novel immuno-oncology therapeutics that target immune suppression in cancer. The company aims to overcome the suppressive effects of myeloid cells to enhance anti-cancer immunity.
